What Idexx Laboratories's Quarter ended Sep 30, 2026 10-Q says: 1 signal
Idexx Laboratories filed its latest 10-Q with the SEC on Nov 2, 2026. It discusses acquisition completed.
Get Idexx Laboratories' live signals in Claude or ChatGPT, or by API
What changed at Idexx Laboratories this week? Use Autobound signals for idexx.com.- Filed
- Nov 2, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 2
- Signals
- 2
Source: Autobound Signal API · 59 signals tracked for Idexx Laboratories · updated
10-Q · latest 2
What Idexx Laboratories's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 1 signal
IDEXX completed the acquisition of CoVet on September 15, 2026
IDEXX acquired CoVet on September 15, 2026, though the revenue impact was immaterial for the period.
- SEC EDGAR
10-Q · Quarter ended Mar 31, 2026
Filed · 1 signal
IDEXX inVue Dx Analyzer Placements Drive 32.7% Diagnostics Instrument Revenue Growth
CAG Diagnostics capital instrument revenue increased 32.7% to $42.449 million primarily due to placements of the IDEXX inVue Dx Analyzer compared to a controlled launch in Q1 2025.
32.7%
CAG Diagnostics capital - instruments revenue reported growth
IDEXX inVue DxTM Analyzer
Earnings calls
Idexx Laboratories earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Q3 organic revenue grew 10% with operating margin at 33.1%Third-quarter revenue expanded 10% organically, led by an 11% organic gain in CAG Diagnostics recurring revenue, with international up 14% and the U.S. up 9.6%. Reported operating margins reached 33.1%, up 60 basis points on a comparable basis, while EPS increased 22% comparably to $4.01. Strong performance indicates high operational cash flow and expanded budget capacity for enterprise tools... | |
| Full-year 2026 revenue guidance raised to $4.754B midpointManagement increased the full-year 2026 revenue range to $4.741B-$4.767B ($4.754B midpoint), an increase of $32 million, reflecting Q3 strength and $5 million from CoVet. Organic revenue growth outlook was lifted to 9.3%-10%, and full-year EPS guidance was increased by $0.25 at midpoint to $14.96-$15.16 per share. This financial headroom highlights stable IT, clinical development, and... | |
| Acquisition of AI clinical assistant provider CoVet finalizedIn September 2026, IDEXX acquired CoVet, an AI-native ambient listening and clinical workflow software vendor generating an annualized revenue run rate of approximately $20 million. Capital deployment reached $335 million across the acquisition and share repurchases in Q3. This creates software integration opportunities across practice management systems, cloud infrastructure, and data workflows. | |
| Launch of Catalyst proBNP and expanded Cancer Dx panelsThe company launched Catalyst proBNP in North America as the first dual-species quantitative point-of-care cardiac test, integrated into VetConnect PLUS. It also rolled out fine needle aspirate (FNA) with canine mast cell tumor detection on inVue Dx to all North American customers, with hemangiosarcoma detection planned for Q1. These platform launches provide entry points for testing supply... | |
| Full-year 2026 capital expenditures updated to approximately $160MCapital spending for full-year 2026 is projected at approximately $160 million, maintaining a free cash flow conversion rate of 95%-100% of net income. Outlays support continuing investments in innovation, global commercial expansions, and IT capabilities. Vendors supplying laboratory equipment, IT infrastructure, and facilities have clear operational spend visibility. | |
| VetLab consumables grew 15% organically driven by menu expansionIDEXX VetLab consumable revenues rose 15% organically, fueled by double-digit growth in both the U.S. and international regions. Growth was bolstered by recurring revenue per inVue Dx analyzer tracking at $3,500-$5,500 alongside expanded menu adoption including Catalyst Pancreatic Lipase and Catalyst Cortisol. This indicates strong recurring consumable spend and expanded laboratory... |
Signal API · MCP
Track Idexx Laboratories with the Signal API
One POST /v1/companies/enrich call with idexx.com returns Idexx Laboratories 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"idexx.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Idexx Laboratories 10-Q
When did Idexx Laboratories file its latest 10-Q?
What did Idexx Laboratories disclose in its latest 10-Q?
What did Idexx Laboratories say on its recent earnings calls?
Where can I read Idexx Laboratories's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .